Resumen

The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye
Active uveitic disease in at least one eye
Currently on one of the following stable treatment regimens for uveitis: oral corticosteroids; systemic immunosuppressive medication; a combination of oral corticosteroids with at least one systemic immunosuppressive medication
Effective contraceptive measures

Criterios de exclusión

Infectious uveitis and masquerade syndromes
Isolated anterior uveitis
Contraindication to mydriatics
History of allergic or anaphylactic reactions to monoclonal antibodies
Active tuberculosis disease
History of recurrent infection or predisposition to infection; active ocular infection
Pregnant or nursing women

Intervenciones

drug

Placebo

Solution for subcutaneous injection

drug

Dose 1 gevokizumab

Solution for subcutaneous injection

drug

Dose 2 gevokizumab

Solution for subcutaneous injection

Ubicaciones

Olivos, Buenos Aires, Argentina

Rosario, Santa Fe Province, Argentina

Buenos Aires, Argentina

Patrocinadores

PrincipalXOMA (US) LLC

ColaboradorInstitut de Recherches Internationales Servier

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Placebo

Dose 1 gevokizumab

Dose 2 gevokizumab

Ubicaciones

Patrocinadores